Q2 2025

Filed Aug 8, 2025 · 10-Q · 39 days after period end · 0001628280-25-039326

Q2 2025 · 10-Q

Revenue

$10.84M

+10.0% vs Q2 2024

Net Income

-$740.74K

N/M vs Q2 2024

EPS Diluted

-$0.05

N/M vs Q2 2024

Operating Income-$3,119,519N/M

Operating Cash Flow

Same quarter

Metric	Q2 2025	Q2 2024	Q2 2023	Q2 2022
Revenue	$10.84M	$9.85M	$10.89M	$10.30M
Net Income	-$740.74K	-$1.09M	$872.20K	-$1.34M
EPS Diluted	-$0.05	-$0.08	$0.06	-$0.09

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Cumberland Pharmaceuticals Inc · CIK 1087294 · Engraved from SEC EDGAR